Arguments in favour of remdesivir for treating SARS-CoV-2 infections

2020/03/05 by Wen-Chien Ko, Wen‐Chien Ko, Jean-Marc Rolain +10 · 2 voices · 1 citation
Medicine · #COVID-19 Clinical Research Studies #SARS-CoV-2 and COVID-19 Research #SARS-CoV-2 detection and testing

paper · doi:10.1016/j.ijantimicag.2020.105933

openalex publication_date 2020/03/05 · crossref created 2020/03/05 · crossref issued 2020/04/01 · crossref published 2020/04/01 · crossref published-print 2020/04/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/13 · crossref indexed 2026/07/20 · openalex updated_date 2026/07/28

Citations

• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
• A Novel Coronavirus from Patients with Pneumonia in China, 2019
• Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
• A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
• First Case of 2019 Novel Coronavirus in the United States
• Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
• Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Cited by

• Estimating epidemiologic dynamics from cross-sectional viral load distributions
• Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths

Discussions

• Remdesivir therapy in the treatment of SARS-CoV-2 infection [hn, 2 points, 0 comments]
• Remdesivir therapy potential for treating SARS-CoV-2 infections [hn, 1 points, 0 comments]